NCT05776979View on ClinicalTrials.gov

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Isatuximab

Given by vein over about 75 minutes

DRUG

lenalidomide

Given by PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05776979 - Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter